{"title":"配体许可托吡酯注射制剂启动曲线","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I8.1973","DOIUrl":null,"url":null,"abstract":"Ligand Pharmaceuticals has licensed global rights to its Captisol-enabled® topiramate injection to start-up CURx Pharmaceuticals for the treatment of partial onset or primary generalised tonic-clonic seizures in hospitalised epilepsy patients who are unable to take oral topiramate. Captisol® is drug formulation system that is designed to optimise the solubility and stability of drugs and which Ligand gained with its 2011 acquisition of CyDex Pharmaceuticals. In a Phase I clinical trial, the drug candidate demonstrated a faster onset of action than oral topiramate.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"117 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ligand Licenses Injectable Formulation of Topiramate to Start-Up CURx\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I8.1973\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ligand Pharmaceuticals has licensed global rights to its Captisol-enabled® topiramate injection to start-up CURx Pharmaceuticals for the treatment of partial onset or primary generalised tonic-clonic seizures in hospitalised epilepsy patients who are unable to take oral topiramate. Captisol® is drug formulation system that is designed to optimise the solubility and stability of drugs and which Ligand gained with its 2011 acquisition of CyDex Pharmaceuticals. In a Phase I clinical trial, the drug candidate demonstrated a faster onset of action than oral topiramate.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"117 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I8.1973\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I8.1973","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ligand Licenses Injectable Formulation of Topiramate to Start-Up CURx
Ligand Pharmaceuticals has licensed global rights to its Captisol-enabled® topiramate injection to start-up CURx Pharmaceuticals for the treatment of partial onset or primary generalised tonic-clonic seizures in hospitalised epilepsy patients who are unable to take oral topiramate. Captisol® is drug formulation system that is designed to optimise the solubility and stability of drugs and which Ligand gained with its 2011 acquisition of CyDex Pharmaceuticals. In a Phase I clinical trial, the drug candidate demonstrated a faster onset of action than oral topiramate.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
